Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2,025 DKK | +66.39% | +4.14% | +14.24% |
05-03 | GENMAB : A good start to 2024; guidance unchanged | |
05-03 | Genmab Posts Q1 Net Profit Surge; Revenue Jumps | MT |
Sales 2024 * | 19.8B 2.87B 3.92B | Sales 2025 * | 23.62B 3.43B 4.67B | Capitalization | 129B 18.65B 25.43B |
---|---|---|---|---|---|
Net income 2024 * | 4.68B 679M 927M | Net income 2025 * | 6.63B 962M 1.31B | EV / Sales 2024 * | 5.16 x |
Net cash position 2024 * | 26.36B 3.82B 5.22B | Net cash position 2025 * | 33.63B 4.88B 6.66B | EV / Sales 2025 * | 4.02 x |
P/E ratio 2024 * |
29.2
x | P/E ratio 2025 * |
21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
+4.11% | 111B | |
+11.42% | 105B | |
-12.59% | 22.34B | |
-3.70% | 21.93B | |
-35.21% | 18.12B | |
-9.80% | 16.96B | |
+2.73% | 13.7B | |
+36.50% | 12.45B | |
+289.20% | 7.98B |